This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Department of Health and Human Services said it would temporarily extend telemedicine flexibilities for the prescription of certain controlled medications granted under the COVID-19 PublicHealth Emergency, which is set to expire on May 11.
health care system, but that are especially present for behavioral health needs like substance use, and are exacerbated by other challenges related to stigma, lack of employment, and fragmented or nonexistent care coordination. This reality reflects structural, policy, and legal misalignments common to the entire U.S.
For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding the prescription of controlled medications established during the COVID-19 PHE will be extended for one year – through November 11, 2024.
Under the Second Temporary Rule, practitioners may continue to prescribe schedule II-V controlled medications via telemedicine for new and existing patients without conducting a prior in-person medical evaluation through 2024.
News In a temporary rule, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental HealthServicesAdministration (SAMHSA) extended telemedicine flexibilities for prescribing controlled medications for six months following the end of the publichealth emergency, through November 11.
Department of Health and Human Services (HHS) and the Substance Abuse and Mental HealthServicesAdministration (SAMHSA) recently released the long anticipated Final Rule to revise the Confidentiality of Substance Use Disorder (SUD) Patient Records regulations at 42 C.F.R. 2] PublicHealth Authority Disclosure.
As a result, if a patient and a practitioner have appropriately established a telemedicine relationship on or before November 11, 2023, the same telemedicine flexibilities that have governed the relationship to that point will continue to be permitted until November 11, 2024.
Longstanding CMS policy has been that, for split or shared visits in an institutional setting, the physician can bill for the services if he/she performs a substantive portion of the encounter. CMS has chosen to extend its phase-in approach of defining “substantive portion” as more than half the time of the visit to CY 2024.
In 2020, specific restrictions on Medicare coverage and reimbursement for telehealth services were waived for the duration of the COVID-19 PublicHealth Emergency (“PHE”) in the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 and the Coronavirus Aid, Relief, and Economic Security Act.
Funding for the Centers for Medicare and Medicaid Services will increase by $100 million, the National Institutes of Health will receive an additional $2.5 This will help to ensure that telehealth and hospital-at-home programs can continue to provide convenient and accessible medical treatment for patients.
However, changes to HIPAA in 2023 are now likely to be implemented, although it may take until 2024 for those changes to become enforceable. Part 2 protects patient privacy and records related to treatment for substance use disorder (SUD) with HIPAA applying to protected health information. Proposed HIPAA Privacy Rule Changes in 2023.
Notably, the Act neither fulfilled the Biden Administration’s request for additional COVID-19 response funding nor included the Verifying Accurate Leading-edge In Vitro Clinical Test (IVCT) Development (VALID) Act, which proposed updating the current diagnostic testing regulatory framework.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content